Cell Therapy
CAR-T Cell Therapy
Nine approved CAR-T products for lymphoma and leukemia. Curative treatment at a fraction of US cost.
9
Approved products
$30K+
Starting price
70%
Complete remission rate
4 weeks
Treatment cycle
Cell Therapy
Nine approved CAR-T products for lymphoma and leukemia. Curative treatment at a fraction of US cost.
World-class outcomes at a fraction of Western cost.
China leads globally with 9 approved CAR-T therapies for B-cell lymphoma and leukemia.
CAR-T costs approximately $30,000–50,000 in China vs. $373,000+ in the US.
Treatment at JCI-accredited oncology centers with dedicated cell therapy units.
Every step — apheresis, manufacturing, infusion and follow-up — coordinated in English.
Comprehensive care across the full spectrum.
For relapsed/refractory diffuse large B-cell lymphoma (DLBCL).
For multiple myeloma after ≥4 prior lines of therapy.
For pediatric B-ALL refractory to standard treatment.
Expert review of your eligibility and treatment plan before committing.
All-inclusive pricing — surgery, hospital stay and standard follow-up.
| Procedure | US Hospital | UK Private | China (HealthBridge) | Save |
|---|---|---|---|---|
| CD19 CAR-T (Lymphoma) | $373,000 | £280,000 | $35,000 | Save 90% |
| BCMA CAR-T (Myeloma) | $465,000 | £350,000 | $40,000 | Save 91% |
| Apheresis + manufacturing | $15,000 | £12,000 | Included | — |
| 30-day post-care monitoring | $20,000 | £15,000 | $5,000 | Save 75% |
From China's top 5 CAR-T cell therapy centers, our experts match you with the best program for your cancer type and stage.
Eligibility depends on prior lines of therapy, disease status and organ function. Submit your records for a free expert review.
Typically 4–6 weeks including apheresis, manufacturing, infusion and 2–4 weeks of monitoring.
All centers have dedicated ICU units for managing cytokine release syndrome (CRS) and ICANS.
You need 2–4 weeks of post-infusion monitoring in-country. After that, follow-up can be coordinated remotely.
Medical Disclaimer: All procedures carry inherent risks (infection, bleeding, anesthesia). Cross-border care adds travel and adaptation risks. HealthBridge is a medical travel coordinator, not a medical provider. Always consult your local physician before making treatment decisions.